Truetide — TickStock

Truetide is signalling a cautious, stewardship-focused approach that prioritises selective oversight and capital allocation over active board intervention across its portfolio.

Updated 24 Jun 2026

Insight

What change did Truetide make in the June 2026 update on Autins?

In the June 2026 update on Autins, Truetide stepped back from day-to-day board representation while preserving the right to nominate a director.

Updated 24 Jun 2026

Insight

Did Truetide give up its contractual appointment rights at Autins when it withdrew representation?

No; Truetide retained the contractual right to appoint a director at Autins even after withdrawing its active board representation.

Updated 24 Jun 2026

Insight

What did Truetide do at portfolio company Autins on 24 June 2026?

On 24 June 2026 Truetide withdrew its active board representation at portfolio company Autins while describing the move as a deliberate step-back based on confidence in Autins' management and operational progress.

Updated 24 Jun 2026

Identifiers

Ticker: TRUE
ISIN: GB00B13XV322

Learn more on:

Official site

Timeline

Paraytec agrees heads of terms with US breath-tech firm VosBio to explore lung cancer detection

More in Healthcare

Cavendish reiterates 'buy' on HUTCHMED with 436p target after 19% share-price slide

The Premarket Brief: easyJet rejects fourth Castlelake bid at £4.93bn, Advanced Medical Solutions, Time Finance, Clean Power Hydrogen, Serco

Agronomics portfolio company Tropic buys banana propagation business Rahan Meristem for $20m

ImmuPharma names Bachem as manufacturing partner for Kapiglucagon drug program

Hutchmed's fanregratinib hits 42.5% response rate in bile duct cancer trial

H.B. Fuller to acquire Advanced Medical Solutions for £695m

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

Health & Bio Today: Thalia Therapeutics acquires AML RNA therapy firm in £2.75m-backed deal, Primary Health Properties, Verici Dx, Beximco Pharmaceuticals, Cambridge Cognition

Cambridge Cognition raises minimum £2.5m to fund regulatory clearances and platform development

Verici Dx clears New York lab certification to complete US nationwide coverage

Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer